心力衰竭与糖尿病共病及其临床用药研究现状  

Status quo of research on comorbidity of heart failure and diabetes and its clinical medication

作　　者：李慧颖 白永怿[1,2] 刘宏斌[1,2,3] LI Hui-Ying;BAI Yong-Yi;LIU Hong-Bin(Department of Cardiology , the Second Medical Center of Chinese PLA General Hospital, Beijing 100853, China;National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing 100853, China;Beijing Key Laboratory of Chronic Heart Failure Precision Medicine, Beijing 100853, China)

机构地区：[1]解放军总医院第二医学中心心血管内科,北京100853 [2]解放军总医院国家老年疾病临床医学研究中心,北京100853 [3]慢性心衰精准医学北京市重点实验室,北京100853

出　　处：《中华老年多器官疾病杂志》2021年第1期62-66,共5页Chinese Journal of Multiple Organ Diseases in the Elderly

基　　金：解放军总医院医疗大数据研发项目(2018MBD-026);国家重点研发计划重点专项课题(2017YFC0840103)。

摘　　要：心力衰竭和糖尿病是现代两种重大的流行病,二者之间交互影响。临床常见心力衰竭与糖尿病共病,对临床用药安全提出了新的挑战。本文从流行病学、临床症状及预后风险、生理病理机制及用药选择4个方面对“心力衰竭与糖尿病共病”的研究现状进行系统阐述,并重点论证将心力衰竭和糖尿病单病药物应用于共病患者的安全性及有效性,为临床用药决策提供指导。Heart failure and diabetes are two most frequent conditions in the modern times that interact with each other.Comorbidity of heart failure and diabetes is clinically common,posing new challenges to the safety of clinical medication.This paper provides a systematical review of the status quo of research on the comorbidity in the aspects of epidemiology,clinical symptoms and risk of prognosis,physiological and pathological mechanism,and drug selection,focusing on the safety and effectiveness of using drugs for heart failure and diabetes for patients with the comorbidity,to provide guidance for decision making in clinical medication.

关 键 词：心力衰竭 糖尿病 共病 

分 类 号：R541.6[医药卫生—心血管疾病] R587.1[医药卫生—内科学]